Massey researcher develops extremely rapid experimental COVID-19 test to accelerate diagnostic turnaround
Early diagnosis and isolation of patients with COVID-19 is a keystone for controlling the pandemic and allowing phased reopening in Virginia. While testing capacity has grown, quick turnaround for patient results remains critical.
To address this need, Rebecca Martin, Ph.D., Massey research member and director of Massey’s Flow Cytometry Core Laboratory, developed an extremely rapid experimental molecular diagnostic assay that decreases the amount of time required to diagnose COVID-19.
“When results can be obtained in just a few minutes, diagnosis and treatment can be provided on the initial care visit without sending samples to a central lab,” said Martin, an assistant professor in the Department of Microbiology and Immunology at the VCU School of Medicine. “This methodology could provide accurate disease diagnostics on-site for immediate personalized clinical management and triage.”
The project was enabled by a grant from the VCU COVID-19 Rapid Research Funding Opportunity, which was established to quickly pivot or expand research addressing the impact of the COVID-19 pandemic on the health system and the community.
Martin collaborated with VCU MD-PhD students Jared Farrar (SOM class of 2022) and Joseph Lownik (SOM class of 2021) to develop the test by using recent methods of fast nucleic acid amplification to screen for SARS-CoV-2, the causative virus for COVID-19.
Their method is combined with rapid RNA extraction from nasopharyngeal swabs and fast reverse transcription to allow for a total detection time of 3.5 minutes from swab to diagnosis. Compared to conventional testing, this new methodology is significantly faster, making the turnaround time minutes rather than hours.
“PCR, a common methodology in research and clinical laboratories, is slow, but sensitive,” said Martin. “Antigen-based testing is fast, but not very sensitive. Our technique is both fast and sensitive.”
Martin’s work builds on research previously conducted by Farrar and Carl Wittwer, M.D., Ph.D., at the University of Utah that demonstrated PCR can be performed in 15-60 seconds.
“By utilizing the principles of Extreme PCR, our test is currently the fastest described molecular diagnostic test for COVID-19 to our knowledge,” said Martin. “Additionally, our technology can be easily multiplexed unlike other rapid molecular diagnostic methods.”
Martin has filed provisional patent applications for this technology. She will also need to obtain FDA approval before the tests can be used on patients.
Her laboratory prototype is currently not practical for testing with patients at the point of care but proves that molecular diagnostic testing for COVID-19 can be done much faster than what current modalities are capable of doing.
For the next steps in their research, Martin and her team will work with the VCU Health System to test their prototype on patient samples as well as apply for funding for building a point-of-care prototype system.
“We look forward to collaborating with the industry to develop an implementation for use in the clinic for COVID-19 diagnostics, as well as syndromic pathogen panels that can be used in testing for many different respiratory pathogens.”